Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study

NCT04472910 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT04472910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma: A Multicentre Canadian Phase II Study
Lead sponsor
University Health Network, Toronto
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 21, 2020
Completion date
December 31, 2026
Enrollment
84 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

resectable pancreatic cancer